drugset / Trial / NCT06757907
Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis
RandomizedParallel-groupOpen-labelTreatment
Summary
Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition
Timeline
- Start
- 2024-10-01
- Primary completion
- 2024-12-20
- Completion
- 2024-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acyclovir | Small molecule | 400 mg | — |
| Comparator | Ganciclovir | Small molecule | 0.15 % | Topical |